Marinol is a prescription medication containing a synthetic form of THC, the primary active compound in cannabis. It has two FDA-approved uses: treating nausea and vomiting caused by chemotherapy, and stimulating appetite in people with AIDS who are losing weight. Beyond these approved uses, doctors sometimes prescribe it for other conditions like obstructive sleep apnea, though the evidence there is still limited.
How Marinol Works in the Body
Marinol’s active ingredient is a lab-made version of delta-9-THC, the same compound responsible for most of marijuana’s effects. It activates cannabinoid receptors found throughout the brain and body. These receptors sit along pathways that regulate hunger, nausea, pain perception, and mood. By switching these receptors on, Marinol can suppress the urge to vomit, increase appetite, and in some cases reduce pain.
Because it’s synthetic THC in capsule form rather than a plant product, Marinol absorbs more slowly than inhaled cannabis. It also stays in the bloodstream longer. This slower, steadier absorption is part of why the effects feel different from smoking or vaping marijuana, with a more gradual onset and a longer duration.
Chemotherapy-Induced Nausea and Vomiting
Marinol’s first FDA approval came in 1985 specifically for cancer patients dealing with nausea and vomiting from chemotherapy. It’s not a first-line treatment. The FDA label specifies it’s for patients who haven’t responded well enough to standard anti-nausea medications. For these patients, Marinol offers an alternative pathway to relief by working through the cannabinoid system rather than the serotonin or dopamine pathways that most conventional anti-nausea drugs target.
For chemotherapy-related nausea, the dose is calculated based on body surface area and is typically taken one to three hours before a chemotherapy session, then every two to four hours afterward for a total of four to six doses per day. This schedule is designed to keep the drug active during the window when nausea peaks.
Appetite Loss and Wasting in AIDS
In 1992, the FDA expanded Marinol’s approved uses to include anorexia and weight loss in people with AIDS. Wasting syndrome, where patients lose significant body mass due to a combination of reduced appetite and metabolic changes, was a serious and common complication before modern antiretroviral therapies became widely available.
The clinical evidence behind this approval is modest. The key study involved 139 patients and found that those taking Marinol were about twice as likely to gain at least 2 kilograms (roughly 4.4 pounds) compared to those on a placebo. However, the average weight gain in the Marinol group was just 0.1 kilograms, compared to a loss of 0.4 kilograms in the placebo group. That’s a real but small difference. Still, for patients who are steadily losing weight and struggling to eat, even a modest improvement in appetite can be meaningful.
For appetite stimulation, the starting dose is typically 2.5 mg taken twice daily, once before lunch and once before dinner.
Off-Label Uses Under Investigation
Doctors sometimes prescribe Marinol for conditions beyond its two approved uses. One area of active research is obstructive sleep apnea. A clinical trial (known as the PACE trial) tested Marinol at doses of 2.5 mg and 10 mg taken before bedtime and found it may help reduce the number of breathing interruptions during sleep. This use is still considered experimental, and Marinol is not FDA-approved for sleep apnea.
Chronic pain is another area where Marinol occasionally shows up in prescriptions. Because cannabinoid receptors play a role in pain signaling, there’s a biological rationale for using it. However, the evidence is less robust than for its approved indications, and it’s typically considered only after other pain management strategies have been tried.
Side Effects to Expect
Marinol is synthetic THC, so its side effects overlap significantly with those of cannabis. The most common include dizziness, drowsiness, euphoria (feeling “high”), and confusion. Some people experience anxiety or paranoia, particularly at higher doses. Nausea, which is ironic given one of its primary uses, can also occur.
These psychological and cognitive effects are dose-dependent, meaning they’re more likely and more intense at higher doses. People who have never used cannabis tend to be more sensitive to these effects than those with prior exposure. The slow absorption of the capsule form means side effects can take an hour or more to appear, which sometimes leads people to take a second dose too soon, compounding the problem.
How Marinol Differs From Medical Marijuana
Marinol contains only synthetic THC. Whole-plant cannabis, by contrast, contains over a hundred different cannabinoids plus terpenes and other compounds that may influence its effects. Some patients and researchers believe this full spectrum of compounds works together in ways that isolated THC does not, though this remains a debated topic.
The practical differences are notable. Marinol comes in standardized capsules (2.5 mg, 5 mg, or 10 mg), so dosing is precise and consistent. Medical marijuana varies widely in potency depending on strain, preparation, and method of consumption. Marinol absorbs more slowly than inhaled cannabis but stays active in the bloodstream longer, which can be either an advantage or a drawback depending on the situation.
Legal Classification
Marinol sits in an unusual legal position. It is classified as a Schedule III controlled substance, meaning it has accepted medical use and a moderate-to-low potential for dependence. Botanical cannabis, by contrast, has historically been classified as Schedule I (no accepted medical use, high abuse potential), though the Department of Justice has proposed moving it to Schedule III as well.
The scheduling distinction matters practically: Schedule III drugs are easier to prescribe, with refills allowed and fewer restrictions on how doctors can call in prescriptions. Marinol was originally placed in Schedule II when first approved in 1985 and was later moved to Schedule III. A related liquid formulation of synthetic THC called Syndros, approved in 2016, remains in the more restrictive Schedule II category.